Audentes Therapeutics Obtains $75,000,000 New Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=8dcfedb6-6193-4a3d-b8f2-e6e6691e44f5 - Date
7/20/2016 - Company Name
Audentes Therapeutics - Mailing Address
101 Montgomery Street. San Francisco, CA 94104 USA - Company Description
Audentes Therapeutics (NASDAQ: BOLD) is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients. - Website
http://www.audentestx.com - Transaction Type
IPO - Transaction Amount
$75,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
We currently intend to use the net proceeds from this offering for the following purposes: approximately $18.0 to $20.0 million to advance AT132 for the treatment of XLMTM through preliminary results from a Phase 1/2 clinical trial expected in the fourth quarter of 2017; approximately $13.0 to $15.0 million to advance AT342 for the treatment of Crigler-Najjar through preliminary results from a Phase 1/2 clinical trial expected in the fourth quarter of 2017; approximately $3.0 to $5.0 million to advance preclinical development of AT982 for the treatment of Pompe disease through preliminary results from a Phase 1/2 clinical trial expected in the second half of 2017; approximately $3.0 to $5.0 million to advance preclinical development of AT307 for the treatment of CASQ2-CPVT through submission of an IND or CTA in 2017; approximately $7.0 to $10.0 million to operate and expand our internal manufacturing facility; and the remainder for working capital and other general corporate purposes, - M&A Terms
